Workflow
Enliven Therapeutics(ELVN)
icon
Search documents
Enliven Therapeutics(ELVN) - 2021 Q1 - Earnings Call Transcript
2021-05-11 19:02
Call Start: 08:30 January 1, 0000 9:02 AM ET Imara, Inc. (IMRA) Q1 2021 Earnings Conference Call May 11, 2021 08:30 ET Company Participants Michael Gray - Chief Financial Officer & Chief Operating Officer Rahul Ballal - President, Chief Executive Officer & Director Conference Call Participants Yigal Nochomovitz - Citigroup Matthew Harrison - Morgan Stanley Joseph Schwartz - SVB Leerink Operator Ladies and gentlemen, thank you for standing by, and welcome to the Imara Inc. Q1 Earnings Conference Call and Web ...
Enliven Therapeutics(ELVN) - 2021 Q1 - Quarterly Report
2021-05-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39247 IMARA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-1523849 (St ...
Enliven Therapeutics(ELVN) - 2020 Q4 - Earnings Call Transcript
2021-03-05 17:39
Imara, Inc. (IMRA) Q4 2020 Earnings Conference Call March 5, 2021 8:30 AM ET Company Participants Michael Gray - CFO & COO Rahul Ballal - President, CEO & Director Conference Call Participants Matthew Harrison - Morgan Stanley Kelly Girskis - SVB Leerink Operator Ladies and gentlemen, thank you for standing by, and welcome to the IMARA Inc. Fourth Quarter Earnings Conference Call and Webcast. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Mr. Mike Gray. Thank yo ...
Enliven Therapeutics(ELVN) - 2020 Q4 - Annual Report
2021-03-04 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39247 IMARA INC. (Exact name of Registrant as specified in its charter) Delaware 81-1523849 (State or other jurisdiction of incorpora ...
Enliven Therapeutics(ELVN) - 2020 Q3 - Earnings Call Transcript
2020-11-07 15:36
IMARA Inc. (IMRA) Q3 2020 Results Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Operating Officer Conference Call Participants Joseph Schwartz - SVB Leerink Yigal Nochomovitz - Citigroup Operator Good morning and welcome to the IMARA Inc. Q3 Earnings Conference Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-an ...
Enliven Therapeutics(ELVN) - 2020 Q3 - Quarterly Report
2020-11-05 12:23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39247 IMARA INC. (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | ...
Enliven Therapeutics(ELVN) - 2020 Q2 - Earnings Call Transcript
2020-08-14 16:14
IMARA Inc. (IMRA) Q2 2020 Results Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Operating Officer Conference Call Participants Yigal Nochomovitz - Citi Group Joseph Schwartz - SVB Leerink Operator Ladies and gentlemen, thank you for standing by and welcome to the IMARA Inc. Q2 earnings conference call and webcast. At this time all participant lines are in a listen-only mode. After the speakers' present ...
Enliven Therapeutics(ELVN) - 2020 Q2 - Quarterly Report
2020-08-14 11:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39247 IMARA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-1523849 (Sta ...
Enliven Therapeutics(ELVN) - 2020 Q1 - Quarterly Report
2020-05-07 12:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39247 IMARA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-1523849 (St ...